End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
7.16 USD | -2.72% | -4.41% | -15.27% |
06-03 | TriSalus Life Sciences, Inc. Highlights Clinical Data from Phase 1b Perio-02 Trial | CI |
05-30 | Canaccord Genuity Initiates TriSalus Life Sciences at Buy Rating With $12 Price Target | MT |